OGT to Host Company Showcase at BioTrinity 2012

Oxford Gene Technology (OGT) will be discussing its biomarker discovery offering at the European Biopartnering and Investment Conference, BioTrinity, from 24th-26th April in Newbury, UK.

The conference will include a Company Showcase from OGT’s CEO, Dr Mike Evans, which takes place at 4.20 pm on Wednesday 25th April.

The talk will provide an overview of OGT’s corporate strategy, which has delivered significant and sustained revenue growth, with particular focus on the company’s Diagnostic Biomarkers business unit.

OGT Diagnostic Biomarkers utilizes proprietary next generation technologies to identify informative biomarkers for early-stage detection of cancer and autoimmune disease.

Through a combination of the implementation of a unique Biomarker Accelerator Strategy and in-house discovery, OGT is building a rich patent-protected portfolio of promising biomarkers for a number of diseases where there are clear clinical needs and markets for improved diagnostic tests.

Details of this strategy and OGT’s additional biomarker discovery and validation services will be given in the presentation.

In a recent example of OGT’s Biomarker Accelerator Strategy, OGT entered into an exclusive licensing deal with Inven2, the technology transfer office at Oslo University Hospital and the University of Oslo.

Using 12 highly promising colorectal cancer tissue biomarkers developed at Oslo University Hospital, OGT now has an exclusive license to commercialize any resulting test developed with the biomarkers.

As a well-established private molecular diagnostics and clinical solutions company actively operating in 30 countries worldwide, OGT has a strong position in the large and rapidly growing molecular medicine market.